Market Overview:

The global women's health diagnostics market size reached US$ 21.62 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 35.7 Billion by 2027, exhibiting at a CAGR of 8.10% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Women's health diagnostics help diagnose various biological and psychosocial conditions of female patients. They assist in addressing sexual and vaginal issues and pregnancy complications and managing threatening diseases, such as osteoporosis, menopause, and certain cancers like breast and cervical. They rely on a series of advanced laboratory tests, tools, and procedures, which include biopsy, ultrasound, chemotherapy, and magnetic resonance imaging (MRI). Several healthcare diagnostics centers are currently offering an expansive range of laboratory testing solutions to enhance the diagnosis and management of rare diseases and conditions that affect women.

Women's Health Diagnostics Market Trends:

The rising prevalence of health issues that impact the overall well-being of women represents one of the major factors influencing the market positively. Moreover, the growing health consciousness, along with the increasing awareness about the benefits of early diagnosis, is catalyzing the demand for point-of-care (POC) women’s health diagnostics across the globe. Apart from this, the rising rate of infertility on account of stressful lifestyles and the growing consumption of alcohol and drugs is driving the need for women’s health diagnostics to address pregnancy complications and ensure a healthier life. Furthermore, as menopause can increase the risk of developing certain medical conditions, including cardiovascular diseases and urinary incontinence, a significant rise in the female population which is over 50 years is contributing to the market growth. Besides this, several research studies have concluded that women are more likely to experience psychiatric disorders, such as depression and anxiety, during hormonal changes. This, in confluence with several initiatives undertaken by health agencies of numerous countries to improve mental health of women, is propelling the market growth across the globe.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global women's health diagnostics market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, application and end user.

Breakup by Type:

• Diagnostic Devices
  • Biopsy Device
  • Imaging and Monitoring Devices
  • Accessories and Consumables
• Diagnostic Tests
  • Breast Cancer Testing
  • PAP Smear and HPV Test
  • Pregnancy Testing and Ovulation Testing
  • Others
     

Breakup by Application:

• Breast Cancer
• Infectious Disease Testing
• Osteoporosis Testing
• Pregnancy and Fertility Testing
• Sexually Transmitted Disease Testing
• Others
   

Breakup by End User:

• Hospital and Diagnostics Centers
• Home Care
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, bioMérieux SA, Cardinal Health Inc., Cook Group Incorporated, F. Hoffmann-La Roche AG, General Electric Company, Hologic Inc., Koninklijke Philips N.V., Perkinelmer Inc., Quest Diagnostics Inc., Siemens AG and Thermo Fisher Scientific Inc.

Report Coverage: